Rimegepant sulfate
Rimegepant sulfate Basic information
- Product Name:
- Rimegepant sulfate
- Synonyms:
-
- [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl]4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
- (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate hemisulfate sesquihydrate
- RIMEGEPANT SULFATE
- Rimegepant sulfate hydrate【Chemical name：1-Piperidinecarboxylic acid, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl ester, sulfate, hydrate (2:1:3)】
- (5S,6S,9R)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b] pyridin-9-yl4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate sesquihydrate
- Rimegepant sulfate hydrate
- Rimegepant hemisulfate sesquihydrate
- Rimegepant 1/2Sulfate 3/2Trihydrate
- CAS:
- 1374024-48-2
- MF:
- C28H30F2N6O7S
- MW:
- 632.64
- EINECS:
- 822-372-0
- Product Categories:
-
- API
- Mol File:
- 1374024-48-2.mol
Rimegepant sulfate Chemical Properties
- InChI
- InChI=1/C28H28F2N6O3.H2O4S/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37;1-5(2,3)4/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37);(H2,1,2,3,4)/t18-,22+,24-;/s3
- InChIKey
- SBWRYPRKGHWPOH-FDZFFRPLNA-N
- SMILES
- S(O)(O)(=O)=O.O=C1NC2=NC=CC=C2N1C1CCN(C(=O)O[C@@H]2CC[C@@H](C3C=CC=C(F)C=3F)[C@H](N)C3=CC=CN=C23)CC1 |&1:22,25,34,r|
Rimegepant sulfate Usage And Synthesis
Description
Rimegepant sulfate is a small molecule, highly selective calcitonin gene-related peptide antagonist (CGRP) developed by Biohaven Pharmaceutical Holdings, Inc. and approved by the FDA for the acute treatment of migraine. rimegepant and ubrogepant are the only CGRP antagonists with oral bioavailability. Because of the absence of vasoconstrictive properties observed with oral CGRP antagonists, the use of rimegepant is safer and more reliable in patients with contraindications to standard therapy[1].
Side effects
Common side effects of Rimegepant sulfate are nausea, which may be severe enough to cause shortness of breath, difficulty breathing; swelling of the face, eyes, mouth, throat, tongue, or lips; rash, measles; and itching.
Synthesis
Rimegepant sulfate is prepared by the reaction of rimegepant and water.
Step: With sulfuric acid In ethanol at 20 - 70℃; Solvent; Temperature.
References
[1] J S. Rimegepant: First Approval.[J]. Drugs, 2020, 80 7: 741-746. DOI:10.1007/s40265-020-01301-3.
Rimegepant sulfateSupplier
- Tel
- +86-0576--88902229 +86-13968687450
- yuxin@yuxchem.com
- Tel
- 025-58741518 13327700685
- sales@vcarepharmatech.com
- Tel
- 028-83379370 13880556291
- tcy@tcypharm.com
- Tel
- 23-86083200-6540
- jia.chen@portonpharma.com
- Tel
- 519-88821493 18915891730
- shm@czpharma.com